Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 4Multiple Myeloma 3Neoplasm Metastasis 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 17Bevacizumab 12Standard of Care 10Cyclophosphamide 9Carboplatin 9Doxorubicin 7Cetuximab 7Nivolumab 6Exercise 6olaparib 5atezolizumab 5Rituximab 5Radiotherapy 5Pemetrexed 5Fluorouracil 5Cisplatin 5durvalumab 4dostarlimab 4abemaciclib 4Temozolomide 4Prednisone 4Paclitaxel 4Leucovorin 4Blood Specimen Collection 4venetoclax 3temsirolimus 3talazoparib 3pertuzumab 3obinutuzumab 3ibrutinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × copanlisib × 30 days × Clear all
NCT03474744 2026-05-06

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

University of Ulm

Phase 2 Active not recruiting
36 enrolled
Lymphoid

Neoplasms, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡